Is SNPHF or XYLD a better dividend investment in 2026?

SNPHF currently yields 2.31% with a 5% 5-year dividend growth rate. XYLD yields 11.20% with 0.5% growth. The better choice depends on your goal: XYLD offers higher current income.

What is the dividend yield difference between SNPHF and XYLD?

SNPHF has a forward dividend yield of 2.31% ($0.25/share annually). XYLD yields 11.20% ($4.30/share annually). The yield gap is 8.89 percentage points.

Home › Compare › SNPHF vs XYLD

SNPHF vs XYLD: Dividend Comparison 2026

SNPHF yields 2.31% · XYLD yields 11.20%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SNPHF wins by $22.3K in total portfolio value

INVESTMENT

TIME HORIZON10 years

SNPHF

● Live price

2.31%

Share price

$10.99

Annual div

$0.25

5Y div CAGR

33.6%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$48.2K

Annual income

$8,450.71

Full SNPHF calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

11.20%

Share price

$38.36

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.9K

Annual income

$3,351.03

Full XYLD calculator →

Portfolio growth — SNPHF vs XYLD

📍 SNPHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SNPHF	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SNPHF + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SNPHF pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNPHF

Annual income on $10K today (after 15% tax)

$196.32/yr

After 10yr DRIP, annual income (after tax)

$7,183.10/yr

XYLD

Annual income on $10K today (after 15% tax)

$952.37/yr

After 10yr DRIP, annual income (after tax)

$2,848.38/yr

At 15% tax rate, SNPHF beats the other by $4,334.73/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNPHF + XYLD for your $10,000?

SNPHF: 50%XYLD: 50%

100% XYLD50/50100% SNPHF

Portfolio after 10yr

$37.0K

Annual income

$5,900.86/yr

Blended yield

15.94%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNPHF buys

XYLD buys

No recent congressional trades found for SNPHF or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSNPHFXYLD

Forward yield	2.31%	11.20% ✓
Annual dividend / share	$0.25	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	33.6% ✓	0%
Portfolio after 10y	$48.2K ✓	$25.9K
Annual income after 10y	$8,450.71 ✓	$3,351.03
Total dividends collected	$24.8K ✓	$20.2K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: SNPHF vs XYLD ($10,000, DRIP)

Year	SNPHF Portfolio	SNPHF Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$11,009	$308.57	$10,840	$1,120.44	+$169.00 → SNPHF
2	$12,203	$424.14	$11,786	$1,249.59	+$417.00 → SNPHF
3	$13,645	$587.05	$12,854	$1,397.78	+$791.00 → SNPHF
4	$15,419	$819.56	$14,063	$1,568.33	+$1.4K → SNPHF
5	$17,655	$1,156.39	$15,434	$1,765.19	+$2.2K → SNPHF
6	$20,544	$1,653.23	$16,995	$1,993.14	+$3.5K → SNPHF
7	$24,384	$2,402.01	$18,777	$2,257.95	+$5.6K → SNPHF
8	$29,651	$3,559.74	$20,818	$2,566.58	+$8.8K → SNPHF
9	$37,131	$5,404.68	$23,163	$2,927.50	+$14.0K → SNPHF
10	$48,181	$8,450.71	$25,865	$3,351.03	+$22.3K → SNPHF

SNPHF vs XYLD: Complete Analysis 2026

SNPHF — Stock

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.

Full SNPHF Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this SNPHF vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNPHF vs SCHD SNPHF vs JEPI SNPHF vs O SNPHF vs KO SNPHF vs MAIN SNPHF vs QYLD SNPHF vs JEPQ SNPHF vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.